2019 - Review, Frontiers in Endocrinology.pdf (2.49 MB)
Endocrine resistance in hormone receptor positive breast cancer–from mechanism to therapy
journal contribution
posted on 2023-06-09, 18:15 authored by Aradhana Rani, Justin Stebbing, Georgios GiamasGeorgios Giamas, John MurphyThe importance and role of the estrogen receptor (ER) pathway has been well-documented in both breast cancer (BC) development and progression. The treatment of choice in women with metastatic breast cancer (MBC) is classically divided into a variety of endocrine therapies, 3 of the most common being: selective estrogen receptor modulators (SERM), aromatase inhibitors (AI) and selective estrogen receptor down-regulators (SERD). In a proportion of patients, resistance develops to endocrine therapy due to a sophisticated and at times redundant interference, at the molecular level between the ER and growth factor. The progression to endocrine resistance is considered to be a gradual, step-wise process. Several mechanisms have been proposed but thus far none of them can be defined as the complete explanation behind the phenomenon of endocrine resistance. Although multiple cellular, molecular and immune mechanisms have been and are being extensively studied, their individual roles are often poorly understood. In this review, we summarize current progress in our understanding of ER biology and the molecular mechanisms that predispose and determine endocrine resistance in breast cancer patients.
History
Publication status
- Published
File Version
- Published version
Journal
Frontiers in EndocrinologyISSN
1664-2392Publisher
Frontiers MediaExternal DOI
Issue
245Volume
10Page range
1-32Department affiliated with
- Biochemistry Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2019-06-28First Open Access (FOA) Date
2019-06-28First Compliant Deposit (FCD) Date
2019-06-27Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC